×
About 2,072 results
CABLIVI (caplacizumab-yhdp) Prescribing Information
http://products.sanofi.us/cablivi/cablivi.pdf

Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

TIBSOVO® (ivosidenib tablets) Prescribing Information
https://www.tibsovopro.com/pdf/prescribinginformation.pdf

Jul 19th, 2018 - TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test

Abbott RealTime IDH1
https://www.molecular.abbott/us/en/products/oncology/realtime-idh1

An in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs)

ADYNOVATE®
http://adynovatepro.com

The official ADYNOVATE site for healthcare professionals.

ADCETRIS® (brentuximab vedotin)
http://adcetrisupdate.com/

Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

ADVATE® [Antihemophilic Factor (Recombinant)]
http://advatepro.com/

The myPKFiT software is intended for use by licensed healthcare professionals (HCPs) who are familiar with hemophilia care. The myPKFiT software can be used to generate ADVATE dosage amount and frequency recommendations for routine prophylaxis for an individual patient 16 years of age and older and body ...

AFSTYLA [Antihemophilic Factor (Recombinant), Single Chain]
http://afstyla.com/hcp

Learn about AFSTYLA, recombinant FVIII therapy that delivers long-lasting bleed protection for patients with hemophilia A. Explore how to sign up your patients for a free 30-day trial.

ARZERRA® (ofatumumab) INJECTION
http://hcp.novartis.com/products/arzerra/

Previously untreated chronic lymphocytic leukemia (CLL) ... In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

BEVYXXA® (betrixaban)
https://www.bevyxxa.com/

HCPs can find information about Bevyxxa, an oral anticoagulant, here.

BENDEKA® INJECTION (bendamustine HCl)
http://bendekahcp.com/

Learn more about BENDEKA (bendamustine HCl) injection, an intravenous chemotherapy for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).

BLINCYTO® INJECTION (blinatumomab)
http://www.blincyto.com/

Find patient and HCP-focused information about BLINCYTO® (blinatumomab). Learn more about acute lymphoblastic leukemia (ALL). See Safety Info, including Boxed Warnings.

BUSULFAN INJECTION
http://www.sagentpharma.com/wpcproduct/busulfan-injection/

Busulfan Injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML)

clonoSEQ® Assay
https://www.adaptivebiotech.com/clonoseq/clonoseq-assay

CLONOSEQ IS THE 1ST AND ONLY FDA-CLEARED ASSAYfor the detection and monitoring of MRD in bone marrow samples from multiple myeloma and B-cell acute lymphoblastic leukemia (ALL) patients

ELOCTATE® (antihemophilic factor (recombinant), Fc fusion protein)
https://www.eloctatepro.com/

Information for healthcare providers about ELOCTATE® [Antihemophilic factor (recombinant), Fc fusion protein].

CALQUENCE® (acalabrutinib) capsule
https://www.calquence.com/physician.html

CALQUENCE is a Bruton tyrosine kinase inhibitor indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.

EMPLICITI™ (elotuzumab) INJECTION
https://www.emplicitihcp.com/

Learn about EMPLICITI™ (elotuzumab) treatment which includes information about ongoing support and resources.

Corifact – Factor XIII Concentrate (Human)
https://www.corifact.com/

Corifact, the first and only FDA-approved, natural FXIII concentrate indicated for routine prophylactic treatment of congenital Factor XIII (FXIII) deficiency.

FEIBA (anti-inhibitor coagulant complex) INTRAVENOUS
https://www.feiba.com/us/hcp/

The official HCP site for FEIBA. Please see Detailed Important Risk Information including BOXED WARNING and full Prescribing Information.

IXINITY® (Coagulation Factor IX (Recombinant)) LYOPHILIZED POWDER FOR SOLUTION FOR INTRAVENOUS INJECTION
http://hcp.ixinity.com/

IXINITY® is a recombinant factor IX hemophilia B treatment option. Healthcare professionals, get IXINITY savings, dosage, and clinical information.